Abstract Library

#4622 Elucidating the role of high mobility group box 3 (Hmgb3) during progression and response to radiation therapy in pancreatic neuroendocrine tumours

Introduction: We have recently demonstrated that HMGB3 is upregulated during the pancreatic neuroendocrine tumours (PanNETs) transition via dedifferentiation from a relatively benign molecular subtype to an aggressive and highly metastatic molecular subtype. HMGB3 expression has recently been linked to resistance to therapy, metastasis, and poor prognosis in patients with various solid cancers.

Conference:

Presenting Author: Kulathunga N

Authors: Kulathunga N, Wang Z, Qureshi A, Lok B, Tyryshkin K,

Keywords: pancreatic neuroendocrine tumour, HMGB3, tumour progression,

#4607 BH3-mimetic drugs elicit cell death of neuroendocrine tumours in preclinical models – An emerging therapeutic strategy for NETs

Introduction: There is an unmet clinical need to identify new, effective therapies for patients with neuroendocrine tumours (NETs). Analysis of single-cell expression data revealed that NETs express high levels of the Bcl2 family of antiapoptotic proteins. Therefore, we hypothesised that proapoptotic drugs, such as BH3-mimetics, can induce programmed cell death, i.e., apoptosis, of neuroendocrine cancer cells.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Kale J, Lens A, Tsui H,

Keywords: neuroendocrine tumour, BH3-mimetics, Navitoclax, Cabozantinib, patient-derived organoids, apoptosis, 177Lu-Dotatate,

#4550 The relationship between MEN1 germline mutations and SSTR2 expression in neuroendocrine tumours

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary disease characterised by the development of multiglandular parathyroid disease, pituitary tumours, and duodenopancreatic neuroendocrine tumours (NETs). Germline mutations in the tumour suppressor gene MEN1 are the underlying cause. Somatostatin receptor 2 (SSTR2) is commonly expressed by NETs. However, the expression of SSTR2 in patients with MEN1 remains unclear.

Conference:

Presenting Author: Chi Y

Authors: Sun Y, Tan H, Wang H, Shi S, Dong L,

Keywords: multiple endocrine neoplasia type 1, somatostatin receptor 2, neuroendocrine tumour,

#4523 Preoperative evaluation of tumour border using radiomics and its surgical guidance in pancreatic neuroendocrine tumours

Introduction: Pancreatic neuroendocrine tumours are a heterogeneous group of tumours originating from peptidergic neurons and neuroendocrine cells with variable survival outcomes. Surgical resection is the mainstay of treatment. However, there is an ambiguous insight into the real need to execute the standard surgery in small pancreatic neuroendocrine tumours. The tumour border is a powerful determinant of survival prognosis in many tumours and is often used as a safety guarantee for parenchyma-sparing resections. However, there are no studies evaluating tumour border with or without preoperative imaging in pNETs.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Gu W, Tang W, Huang D, Zhang W,

Keywords: pancreatic neuroendocrine tumour, border, computed tomography, enucleation, radiomics,

#4514 Liver debulking surgery is benefit to PFS in patients with high tumour burden of neuroendocrine tumour liver metastases

Introduction: Liver debulking surgery has shown its definite effect on prolonging survival in patients with neuroendocrine tumour liver metastases (NETLM). However, the effect of liver debulking surgery on the high burden of NETLM is still not clear.

Conference:

Presenting Author:

Authors: Zhou J, Liang Y, Chen J, Wang L,

Keywords: liver debulking surgery, NETLM,